The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome–associated Renal Cancer: Recognition of the Syndrome by Pathologic Features and the Utility of Detecting Aberrant Succination by Immunohistochemistry
Open accessAbstract
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is an autosomal dominant disorder in which germline mutations of fumarate hydratase (FH) gene confer an increased risk of cutaneous and uterine leiomyomas and renal cancer. HLRCC-associated renal cancer is highly aggressive and frequently presents as a solitary mass. We reviewed the clinicopathologic features of 9 patients with renal tumors presenting as sporadic cases but who were later proven to have FH germline mutations. Histologically, all tumors showed mixed architectural patterns, with papillary as the dominant pattern in only 3 cases. Besides papillary, tubular, tubulopapillary, solid, and cystic elements, 6 of 9 tumors contained collecting duct carcinoma-like areas with infiltrating tubules, nests, or individual cells surrounded by desmoplastic stroma. Prominent tubulocystic carcinoma-like component and sarcomatoid differentiation were identified. Although all tumors exhibited the proposed hallmark of HLRCC (large eosinophilic nucleolus surrounded by a clear halo), this feature was often not uniformly present throughout the tumor. Prior studies have shown that a high level of fumarate accumulated in HLRCC tumor cells causes aberrant succination of cellular proteins by forming a stable chemical modification, S-(2-succino)-cysteine (2SC), which can be detected by immunohistochemistry. We thus explored the utility of detecting 2SC by immunohistochemistry in the differential diagnosis of HLRCC tumors and other high-grade renal tumors and investigated the correlation between 2SC staining and FH molecular alterations. All confirmed HLRCC tumors demonstrated diffuse and strong nuclear and cytoplasmic 2SC staining, whereas all clear cell (184/184, 100%), most high-grade unclassified (93/97, 96%), and the large majority of "type 2" papillary (35/45, 78%) renal cell carcinoma cases showed no 2SC immunoreactivity. A subset of papillary (22%) and rare unclassified (4%) tumors showed patchy or diffuse cytoplasmic staining without nuclear labeling, unlike the pattern seen with confirmed HLRCC tumors. Sequencing revealed no germline or somatic FH alterations in 14 tumors that either exhibited only cytoplasmic 2SC staining (n=5) or were negative for 2SC (n=9), despite their HLRCC-like morphologic features. Our results emphasize the pivotal role of pathologic examination in the diagnosis of HLRCC patients and indicate immunohistochemical detection of 2SC as a useful ancillary tool in the differentiation of HLRCC renal tumors from other high-grade renal cell carcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., Philippakis, A. A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,456
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia
Srigley, J. R., Delahunt, B., Eble, J. N., Egevad, L., Epstein, J. I., Grignon, D., Hes, O., Moch, H., Montironi, R., Tickoo, S. K., et al. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318299f2d1 · Cited by 1,047
Self-citationPapillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors.
Delahunt, B., & Eble, J. N. (1997) · PubMed · Cited by 714
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al-Ahmadie, H., Scott, S. N., Janakiraman, M., Pirun, M., Sander, C., Socci, N. D., Ostrovnaya, I., et al. (2012) · Science · doi:10.1126/science.1226344 · Cited by 690
Self-citationInherited susceptibility to uterine leiomyomas and renal cell cancer
Launonen, V., Vierimaa, O., Kiuru, M., Isola, J., Roth, S., Pukkala, E., Sistonen, P., Herva, R., & Aaltonen, L. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633798 · Cited by 669
Toro, J. R., Nickerson, M. L., Wei, M.-H., Warren, M. B., Glenn, G. M., Turner, M. L., Stewart, L., Duray, P., Tourre, O., Sharma, N., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/376435 · Cited by 634
Merino, M. J., Torres-Cabala, C., Pinto, P., & Marston Linehan, W. (2007) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31804375b8 · Cited by 409
Cited by
Menko, F. H., Maher, E. R., Schmidt, L. S., Middelton, L. A., Aittomäki, K., Tomlinson, I., Richard, S., & Linehan, W. M. (2014) · Familial Cancer · doi:10.1007/s10689-014-9735-2 · Cited by 356
Young, M., Jackson-Spence, F., Beltran, L., Day, E., Suarez, C., Bex, A., Powles, T., & Szabados, B. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00917-6 · Cited by 271
Trpkov, K., Hes, O., Williamson, S. R., Adeniran, A. J., Agaimy, A., Alaghehbandan, R., Amin, M. B., Argani, P., Chen, Y.-B., Cheng, L., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00779-w · Cited by 258
Self-citationTrpkov, K., Hes, O., Agaimy, A., Bonert, M., Martinek, P., Magi-Galluzzi, C., Kristiansen, G., Lüders, C., Nesi, G., Compérat, E., et al. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000617 · Cited by 255
Self-citationImmunotherapy in Renal Cell Carcinoma: The Future Is Now
Deleuze, A., Saout, J., Dugay, F., Peyronnet, B., Mathieu, R., Verhoest, G., Bensalah, K., Crouzet, L., Laguerre, B., Belaud-Rotureau, M.-A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072532 · Cited by 198
Metadata
- Authors
- Chen, Y.-B., Brannon, A. R., Toubaji, A., Dudas, M. E., Won, H. H., Al-Ahmadie, H. A., Fine, S. W., Gopalan, A., Frizzell, N., Voss, M. H., Russo, P., Berger, M. F., Tickoo, S. K., & Reuter, V. E.
- Venue
- American Journal of Surgical Pathology
- Published
- 2014-05
- Volume
- 38
- Issue
- 5
- Pages
- 627-637
- ISSN
- 0147-5185 (ISSN-L)
- OpenAlex
- W2080212907
- Cited by
- 276
- References
- 21
- FWCI
- 16.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome–associated Renal Cancer: Recognition of the Syndrome by Pathologic Features and the Utility of Detecting Aberrant Succination by Immunohistochemistry. https://app.cochat.ai/papers/10.1097/pas.0000000000000163
- The paper
- Chen, Y.-B., Brannon, A. R., Toubaji, A., Dudas, M. E., Won, H. H., Al-Ahmadie, H. A., Fine, S. W., Gopalan, A., Frizzell, N., Voss, M. H., Russo, P., Berger, M. F., Tickoo, S. K., & Reuter, V. E. (2014). Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome–associated Renal Cancer: Recognition of the Syndrome by Pathologic Features and the Utility of Detecting Aberrant Succination by Immunohistochemistry. American Journal of Surgical Pathology. https://doi.org/10.1097/pas.0000000000000163
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.